儿童脑型肾上腺脑白质营养不良无环孢素单倍体移植结局
该回顾性研究纳入26例接受优化无环孢素GVHD预防方案(ATG 4 mg/kg、PTCy、MMF)的单倍体HSCT的儿童脑型肾上腺脑白质营养不良患者。中位随访29个月,总生存90.4%±6.6%,无重大功能残疾生存69.0%±9.1%,移植后C26:0水平及C24:0/C22:0、C26:0/C22:0比值显著下降,MRI LOES评分基本稳定。结果支持该方案安全有效,需前瞻性验证。
要点
- 无环孢素单倍体HSCT方案在儿童cALD中可行,中位随访29个月总生存90.4%。
- 移植后血浆C26:0水平及C24:0/C22:0、C26:0/C22:0比值显著下降。
- 移植后MRI LOES评分基本稳定,未显著进展。
核心结论
- 优化无环孢素单倍体HSCT方案在儿童cALD中显示安全有效,值得前瞻性研究验证。
研究设计与样本
- 回顾性分析26例接受单倍体HSCT的儿童cALD患者。
- GVHD预防采用ATG 4 mg/kg、PTCy和吗替麦考酚酯的无环孢素方案。
主要发现
- 中性粒细胞和血小板植入中位时间均为15天(范围分别为13-26天和9-33天)。
- 100天II-IV级急性GVHD累积发生率为18.49%±8.37%,3年中重度慢性GVHD累积发生率为9.32%±6.28%。
- 中位随访29个月,总生存为90.4%±6.6%,无重大功能残疾生存为69.0%±9.1%。
- 移植后血浆C26:0水平及C24:0/C22:0、C26:0/C22:0比值显著下降。
- 移植后平均7.3±5.9个月MRI显示LOES评分基本稳定,无显著进展。
临床怎么用
- 对于儿童cALD,可考虑采用无环孢素的单倍体HSCT GVHD预防方案以降低神经毒性风险。
局限性
- 回顾性研究,样本量26例,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) expands donor availability for cerebral adrenoleukodystrophy (cALD). However, conventional graft-versus-host disease (GVHD) prophylaxis based on calcineurin inhibitors like ciclosporin (CsA) poses a potential neurotoxicity risk that may exacerbate neurological injury. We retrospectively analysed 26 cALD patients who underwent haplo-HSCT with an optimized ciclosporin-free GVHD prophylaxis regimen consisting of anti-thymocyte globulin (ATG; 4 mg/kg), post-transplant cyclophosphamide (PTCy) and mycophenolate mofetil. Neutrophil and platelet engraftment each occurred at a median of 15 days (ranges, 13-26 and 9-33 days respectively). The cumulative incidence (CI) of grades II-IV acute GVHD by day 100 was 18.49% ± 8.37%, and the 3-year CI of moderate-to-severe chronic GVHD was 9.32% ± 6.28%. After a median follow-up of 29 months, overall survival was 90.4% ± 6.6% and major functional disability-free survival was 69.0% ± 9.1%. Post-transplantation, plasma C26:0 levels and the C24:0/C22:0 and C26:0/C22:0 ratios were markedly reduced. Magnetic resonance imaging (MRI) at a mean of 7.3 ± 5.9 months post-HSCT showed largely preserved LOES scores without significant progression. Our experience supports the safety and efficacy of this optimized ciclosporin-free haplo-HSCT approach for patients with cALD, warranting further validation in prospective studies.
引用
- Ye F, Fu B, Chen K, et al. Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy. Br J Haematol. 2026. PMID: 42152527. doi:10.1111/bjh.70561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。